| 1. |
- Bahce, Idris, et al.
(author)
-
Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
- 2013
-
In: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 19:1, s. 183-193
-
Journal article (peer-reviewed)abstract
- PURPOSE: To evaluate whether, in patients with non-small cell lung carcinoma (NSCLC), tumor uptake of [(11)C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of tracer uptake corresponds with the presence of activating tumor EGF receptor (EGFR) mutations.EXPERIMENTAL DESIGN: Ten patients with NSCLCs, five with an EGFR exon 19 deletion, and five without were scanned twice (test retest) on the same day with an interval of at least 4 hours. Each scanning procedure included a low-dose computed tomographic scan, a 10-minute dynamic [(15)O]H(2)O scan, and a 1-hour dynamic [(11)C]erlotinib scan. Data were analyzed using full tracer kinetic modeling. EGFR expression was evaluated using immunohistochemistry.RESULTS: The quantitative measure of [(11)C]erlotinib uptake, that is, volume of distribution (V(T)), was significantly higher in tumors with activating mutations, that is, all with exon 19 deletions (median V(T), 1.76; range, 1.25-2.93), than in those without activating mutations (median V(T), 1.06; range, 0.67-1.22) for both test and retest data (P = 0.014 and P = 0.009, respectively). Good reproducibility of [(11)C]erlotinib V(T) was seen (intraclass correlation coefficient = 0.88). Intergroup differences in [(11)C]erlotinib uptake were not correlated with EGFR expression levels, nor tumor blood flow.CONCLUSION: [(11)C]erlotinib V(T) was significantly higher in NSCLCs tumors with EGFR exon 19 deletions.
|
|
| 2. |
- Thunnissen, Erik, et al.
(author)
-
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group
- 2012
-
In: Lung Cancer. - : Elsevier BV. - 1872-8332 .- 0169-5002. ; 76:1, s. 1-18
-
Research review (peer-reviewed)abstract
- Until recently, the division of pulmonary carcinomas into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) was adequate for therapy selection. Due to the emergence of new treatment options subtyping of NSCLC and predictive testing have become mandatory. A practical approach to the new requirements involving interaction between pulmonologist, oncologist and molecular pathology to optimize patient care is described. The diagnosis of lung cancer involves (i) the identification and complete classification of malignancy, (ii) immunohistochemistry is used to predict the likely NSCLC subtype (squamous cell vs. adenocarcinoma), as in small diagnostic samples specific subtyping is frequently on morphological grounds alone not feasible (NSCLC-NOS), (iii) molecular testing. To allow the extended diagnostic and predictive examination (i) tissue sampling should be maximized whenever feasible and deemed clinically safe, reducing the need for re-biopsy for additional studies and (ii) tissue handling, processing and sectioning should be optimized. Complex diagnostic algorithms are emerging, which will require close dialogue and understanding between pulmonologists and others who are closely involved in tissue acquisition, pathologists and oncologists who will ultimately, with the patient, make treatment decisions. Personalized medicine not only means the choice of treatment tailored to the individual patient, but also reflects the need to consider how investigative and diagnostic strategies must also be planned according to individual tumour characteristics. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
|
|
| 3. |
- Thunnissen, Marjolein, et al.
(author)
-
BioMAX: The Future Macromolecular Crystallography Beamline at MAX IV
- 2013
-
In: 11th International Conference on Synchrotron Radiation Instrumentation (SRI 2012). - : IOP Publishing. - 1742-6596 .- 1742-6588. ; 425
-
Conference paper (peer-reviewed)abstract
- This paper describes the preliminary design of the BioMAX beamline at the 3 GeV ring of the MAX IV facility, focusing on the optics and x-ray beam performance. The MAX IV facility will include two storage rings with 1.5 GeV and 3.0 GeV electron energy and a linac serving both as injector for the two rings and feeding a short pulse facility. BioMAX is one of the first seven beamlines funded at the MAX IV facility. It is a multipurpose high-throughput beamline for macromolecular crystallography. The beamline aims to be robust and simple to operate with a beam benefiting from the properties of the MAX IV 3 GeV ring. However it does not aim at the smallest beam or crystal sizes since it is foreseen that it will be complemented with a microfocus beamline aiming at a beam size of 1 mu m. The beamline experiment setup will be highly automated, both in terms of sample handling hardware and data analysis, including feedback to the data collection. The BioMAX beamline is planned to be in operation in 2016.
|
|
